Literature DB >> 2578079

Serum alpha-fetoprotein subfractions in patients with primary hepatoma or hepatic metastasis of gastric cancer.

T Ishiguro, I Sugitachi, H Sakaguchi, S Itani.   

Abstract

Alpha-fetoprotein (AFP) subfractions were studied in 38 sera including 34 patients with primary hepatoma and 4 from patients with hepatic metastasis of gastric cancer. Fractionation of AFP was carried out by concanavalin A (Con A) or lentil lectin (LCH) crossed-line affinity immunoelectrophoresis. With use of Con A, fetal-liver-originated subfraction (peak a) was commonly found in both primary hepatoma and metastatic liver cancer, while yolk-sac-originated subfraction (peak b) was detected in 7 of 34 (20.6%) primary hepatomas and 4 of 4 (100%) metastatic liver cancers. With use of LCH, fetal-liver-originated subfractions (peaks A and/or C) were commonly found in both primary hepatoma and hepatic metastasis of gastric cancer, while yolk-sac-originated subfraction (peak B) was found only in metastatic liver cancer. These findings suggest that glycosylation of AFP in primary hepatoma differs from that in hepatic metastasis of gastric cancer. It is also suggested that AFP synthesized in hepatic cancers and fetal liver are differently glycosylated and AFP synthesis of hepatic malignancies are not always retrogenetically expressed, as in case of the fetal liver. Clinically, different patterns of AFP subfraction identified by Con A or LCH crossed-line affinity immunoelectrophoresis facilitate a differential diagnosis of primary hepatoma and hepatic metastasis of gastric cancer, in cases of elevated serum AFP levels. In the current study, attention was also given to the retrogenetic expression of AFP synthesis in hepatic metastasis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578079     DOI: 10.1002/1097-0142(19850101)55:1<156::aid-cncr2820550124>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Establishment and characterization of HEPFT, a cell line derived from hepatoid carcinoma of the fallopian tube, with special reference to alpha-fetoprotein, lectin affinity and histogenesis.

Authors:  Iwao Ishiwata; Makoto Yasuda; Takashi Hirano; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2007-11       Impact factor: 4.174

2.  Serum alpha-fetoprotein subfractions in hepatic malignancies identified by different reactivities with concanavalin A, lentil lectin or phytohemagglutinin-E.

Authors:  T Ishiguro; H Sakaguchi; M Fukui; I Sugitachi
Journal:  Jpn J Surg       Date:  1986-01

3.  Double cancer of the stomach, one AFP-producing tumor.

Authors:  T Hyodo; R Kawamoto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

4.  Alpha-fetoprotein-producing esophageal adenocarcinoma: report of a case.

Authors:  H Sawada; A Watanabe; Y Yamada; T Yano; H Nakano; Y Konishi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Alpha-fetoprotein-producing early gastric cancer accompanying liver cirrhosis: a case report.

Authors:  Y Umekawa; M Watanabe; S Ikeda; S Fukumoto; H Hirakawa; Y Shimada
Journal:  J Gastroenterol       Date:  1994-02       Impact factor: 7.527

6.  Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.

Authors:  Y Aoyagi; Y Suzuki; K Igarashi; A Saitoh; M Oguro; T Yokota; S Mori; T Suda; M Isemura; H Asakura
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

7.  Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml--a study based on 4,312 patients.

Authors:  Qi-wen Chen; Chien-shan Cheng; Hao Chen; Zhou-yu Ning; Shi-feng Tang; Xun Zhang; Xiao-yan Zhu; Sonya Vargulick; Ye-hua Shen; Yong-qiang Hua; Jing Xie; Wei-dong Shi; Hui-feng Gao; Li-tao Xu; Lan-yun Feng; Jun-hua Lin; Zhen Chen; Lu-ming Liu; Bo Ping; Zhi-qiang Meng
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.